Metabolic syndrome: An evolving concept;Síndrome metabólica: Um conceito em evolução

Revista Portuguesa de Cardiologia

Volumn 26, Issue 12, 2007, Pages 1409-1421

  Cortez Dias, Nuno ^a   Martins, Susana ^a   Fiuza, Manuela ^a,b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b NONE   (Portugal)

Author keywords

Arterial hypertension; Diabetes; Dyslipidemia; Metabolic syndrome; Obesity; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; REVIEW; WEIGHT REDUCTION;

HUMANS; METABOLIC SYNDROME X;

EID: 39349086826     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12):1595-1607.
2. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139(10):802-809.
3. Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro A III, et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157(8):701-711.
4. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26(8):2442-2450.
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21):2709-2716.
6. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110(10):1251-1257.
7. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49(4):403-414.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15(7):539-553.
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143-3421.
10. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366(9491):1059-1062.
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17):2735-2752.
12. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109(4):551-556.
13. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006; 48(2):293-297.
14. Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49(12):2837-2846.
15. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48(9):1684-1699.
16. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3):391-397.
17. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108(4):414-419.
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6):2548-2556.
19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3):356-359.
20. Santos AC, Lopes C, Barros H. Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol 2004; 23(1):45-52.
21. von Hafe P, Lopes C, Maciel MJ, Barros H. [The clustering of cardiovascular risk factors in the urban population of Porto]. Acta Med Port 1998; 11(12):1059-1064.
22. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11):987-1003.
23. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18):1837-1847.
24. Colwell JA. Is aspirin effective in diabetic patients? Yes. J Thromb Haemost 2005; 3(12):2612-2614.
25. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164(9):994-1003.
26. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334(7588):299.
27. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27(1):73-100.
28. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365(9468):1389-1397.
29. Shah M, Adams-Huet B, Bantle JP, Henry RR, Griver KA, Raatz SK et al. Effect of a high-carbohydrate versus a high - cis-monounsaturated fat diet on blood pressure in patients with type 2 diabetes. Diabetes Care 2005; 28(11):2607-2612.
30. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162(22):2597-2604.
31. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97(4):477-479.
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-1252.
33. Abuissa H, Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46(5):821-826.
34. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48(3):385-391.
35. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.
36. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004; 47(6):969-975.
37. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54(4):1150-1156.
38. Campbell IW. The Clinical Significance of PPAR Gamma Agonism. Curr Mol Med 2005; 5(3):349-363.
39. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24):2457-2471.
40. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357(1):28-38.